Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fvets.2020.603622 http://scihub22266oqcxt.onion/10.3389/fvets.2020.603622 33240967!7677234!33240967     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Vet+Sci 2020 ; 7 (ä): 603622 Nephropedia Template TP {{tp|p=33240967|t=2020. Bovine Interferon Lambda Is a Potent Antiviral Against SARS-CoV-2 Infection in vitro |pdf=|usr=}}{{33240967}} gab.com Text Bovine Interferon Lambda Is a Potent Antiviral Against SARS-CoV-2 Infection in vitro JO: Front Vet Sci http://www.kidney.de/pget.php?&tw=1&pmid=33240967 #FOAvip Interferon lambda (IFN-lambda) is an antiviral naturally produced in response to viral infections, with activity on cells of epithelial origin and located in the mucosal surfaces. This localized activity results in reduced toxicity compared to type I IFNs, whose receptors are ubiquitously expressed. IFN-lambda has been effective in the therapy of respiratory viral infections, playing a crucial role in potentiating adaptive immune responses that initiate at mucosal surfaces. Human IFN-lambda has polymorphisms that may cause differences in the interaction with the specific receptor in the human population. Interestingly, bovine IFN-lambda3 has an in silico-predicted higher affinity for the human receptor than its human counterparts, with high identity with different human IFN-lambda variants, making it a suitable antiviral therapeutic candidate for human health. Here, we demonstrate that a recombinant bovine IFN-lambda (rbIFN-lambda) produced in HEK-293 cells is effective in preventing SARS-CoV-2 infection of VERO cells, with an inhibitory concentration 50% (IC50) between 30 and 50 times lower than that of human type I IFN tested here (alpha2b and beta1a). We also demonstrated the absence of toxicity of rbIFN-lambda in human PBMCs and the lack of proinflammatory activity on these cells. Altogether, our results show that rbIFN-lambda is as an effective antiviral potentially suitable for COVID-19 therapy. Among other potential applications, rbIFN-lambda could be useful to preclude virus dispersion to the lungs and/or to reduce transmission from infected people. Moreover, and due to the non-specific activity of this IFN, it can be potentially effective against other respiratory viruses that may be circulating together with SARS-CoV-2. Twit Text FOAVip Bovine Interferon Lambda Is a Potent Antiviral Against SARS-CoV-2 Infection in vitro ????Front Vet Sci http://www.kidney.de/pget.php?&tw=1&pmid=33240967 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33240967 #FOAvip English Wikipedia <ref>{{Cite pmid|33240967}}</ref> Bovine Interferon Lambda Is a Potent Antiviral Against SARS-CoV-2 Infection in vitro #MMPMID33240967 Cardoso NP; Mansilla FC; Benedetti E; Turco CS; Barone LJ; Iserte JA; Soria I; Baumeister E; Capozzo AV Front Vet Sci 2020[]; 7 (ä): 603622 PMID33240967show ga Interferon lambda (IFN-lambda) is an antiviral naturally produced in response to viral infections, with activity on cells of epithelial origin and located in the mucosal surfaces. This localized activity results in reduced toxicity compared to type I IFNs, whose receptors are ubiquitously expressed. IFN-lambda has been effective in the therapy of respiratory viral infections, playing a crucial role in potentiating adaptive immune responses that initiate at mucosal surfaces. Human IFN-lambda has polymorphisms that may cause differences in the interaction with the specific receptor in the human population. Interestingly, bovine IFN-lambda3 has an in silico-predicted higher affinity for the human receptor than its human counterparts, with high identity with different human IFN-lambda variants, making it a suitable antiviral therapeutic candidate for human health. Here, we demonstrate that a recombinant bovine IFN-lambda (rbIFN-lambda) produced in HEK-293 cells is effective in preventing SARS-CoV-2 infection of VERO cells, with an inhibitory concentration 50% (IC50) between 30 and 50 times lower than that of human type I IFN tested here (alpha2b and beta1a). We also demonstrated the absence of toxicity of rbIFN-lambda in human PBMCs and the lack of proinflammatory activity on these cells. Altogether, our results show that rbIFN-lambda is as an effective antiviral potentially suitable for COVID-19 therapy. Among other potential applications, rbIFN-lambda could be useful to preclude virus dispersion to the lungs and/or to reduce transmission from infected people. Moreover, and due to the non-specific activity of this IFN, it can be potentially effective against other respiratory viruses that may be circulating together with SARS-CoV-2. äBovine Interferon Lambda Is a Potent Antiviral Against SARS-CoV-2 Infe(epmc).pdf DeepDyve Pubget Overpricing